Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 20;130(2):224-230.
doi: 10.4103/0366-6999.198009.

Factors Associated with the Size of HIV DNA Reservoir

Ni-Dan Wang  1 , Tai-Sheng Li  1
Affiliations
Review

Factors Associated with the Size of HIV DNA Reservoir

Ni-Dan Wang et al. Chin Med J (Engl). .

Abstract

Objective: To review the recent literatures related to the factors associated with the size of the HIV reservoir and their clinical significance.

Data sources: Literatures related to the size of HIV DNA was collected from PubMed published from 1999 to June 2016.

Study selection: All relevant articles on the HIV DNA and reservoir were collected and reviewed, with no limitation of study design.

Results: The composition and development of the HIV-1 DNA reservoir in either treated or untreated patients is determined by integrated mechanism comprising viral characteristics, immune system, and treatment strategies. The HIV DNA reservoir is a combination of latency and activity. The residual viremia from the stochastic activation of the reservoir acts as the fuse, continuing to stimulate the immune system to maintain the activated microenvironment for the rebound of competent virus once treatment with antiretroviral therapy is discontinued.

Conclusion: The size of the HIV-1 DNA pool and its composition has great significance in clinical treatment and disease progression.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
The composition and development of the HIV-1 DNA reservoir either in treated or untreated patients is determined by integrated mechanism comprising viral characteristics, immune system, and drugs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF) Biochem Pharmacol. 2016;119:1–7. doi:10.1016/j.bcp.2016.04.015. - PubMed
    1. Swartz JE, Vandekerckhove L, Ammerlaan H, de Vries AC, Begovac J, Bierman WF, et al. Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. J Antimicrob Chemother. 2015;70:1850–7. doi:10.1093/jac/dkv033. - PubMed
    1. Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, et al. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: A prospective, multicenter study in China. Chin Med J. 2014;127:59–65. doi:10.3760/cma.j.issn.0366-6999.20132557. - PubMed
    1. Kimata JT, Rice AP, Wang J. Challenges and strategies for the eradication of the HIV reservoir. Curr Opin Immunol. 2016;42:65–70. doi:10.1016/j.coi.2016.05.015. - PMC - PubMed
    1. Craigie R, Bushman FD. HIV DNA integration. Cold Spring Harb Perspect Med. 2012;2:a006890. doi:10.1101/cshperspect.a006890. - PMC - PubMed